There is an error in Table 3. The number of samples (n = X) are incorrect. Please see the correct Table 3 here.
Table 3. Diagnostic performance of NAAT assays.
| Test (target region) | Positive result for samples with <100 copies/mL (n = 14) | Positive result for samples with ≥100 copies/mL (n = 8) | Sensitivity [95% CI] (n = 69) | Specificity [95% CI] (n = 69) |
|---|---|---|---|---|
| NIID | 13 (92.9%) | 8 (100%) | 95.5% [77.2%-99.9%] |
100% [88.9%-100%] |
| NIID (NIID-N) | 6 (42.9%) | 8 (100%) | 63.6% [40.7%-82.8%] |
100% [88.9%-100%] |
| NIID (NIID-N2) | 13 (92.9%) | 8 (100%) | 95.5% [77.2%-99.9%] |
100% [88.9%-100%] |
| FUJIFILM | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
| FUJIFILM (NIID-N) | 0 (0%) | 5 (62.5%) | 22.7% [7.8%-45.4%] |
100% [88.9%-100%] |
| FUJIFILM (NIID-N2) | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
| NCV-101, -102 | 7 (50%) | 8 (100%) | 68.2% [45.1%-86.1%] |
100% [88.9%-100%] |
| NCV-101 (NIID-N) | 2 (14.3%) | 6 (75%) | 36.4% [17.2%-59.3%] |
100% [88.9%-100%] |
| NCV-102 (NIID-N2) | 6 (42.9%) | 8 (100%) | 63.6% [40.7%-82.8%] |
100% [88.9%-100%] |
| SHIMADZU | 12 (85.7%) | 8 (100%) | 90.9% [70.8%-98.9%] |
100% [88.9%-100%] |
| SHIMADZU (CDC-N1) | 11 (78.6%) | 8 (100%) | 86.4% [65.1%-97.1%] |
100% [88.9%-100%] |
| SHIMADZU (CDC-N2) | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
| NCV-301, -302 | 9 (64.3%) | 8 (100%) | 77.3% [54.6%-92.2%] |
100% [88.9%-100%] |
| NCV-301 (CDC-N1) | 7 (50%) | 8 (100%) | 68.2% [45.1%-86.1%] |
100% [88.9%-100%] |
| NCV-302 (CDC-N2) | 7 (50%) | 8 (100%) | 68.2% [45.1%-86.1%] |
100% [88.9%-100%] |
| NCV-403 | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
| NCV-403 (CDC-N1) | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
| NCV-403 (CDC-N2) | 6 (42.9%) | 8 (100%) | 63.6% [40.7%-82.8%] |
100% [88.9%-100%] |
| TaKaRa (CDC-N1, CDC-N2) | 11 (78.6%) | 8 (100%) | 86.4% [65.1%-97.1%] |
100% [88.9%-100%] |
| KANEKA (CDC-N1, CDC-N2) | 12 (85.7%) | 8 (100%) | 90.9% [70.8%-98.9%] |
100% [88.9%-100%] |
| LAMP (N, RdRP) | 10 (71.4%) | 8 (100%) | 81.8% [59.7%-94.8%] |
100% [88.9%-100%] |
The publisher apologizes for the error.
Reference
- 1.Mizoguchi M, Harada S, Okamoto K, Higurashi Y, Ikeda M, Moriya K (2021) Comparative performance and cycle threshold values of 10 nucleic acid amplification tests for SARS-CoV-2 on clinical samples. PLoS ONE 16(6): e0252757. 10.1371/journal.pone.0252757 [DOI] [PMC free article] [PubMed] [Google Scholar]